Showing results (461-470 of 505) with videos related to

Sort By:
Pageof 51
The Journal of Clinical Investigation|October 4, 2006
VSIG4, a B7 family-related protein, is a negative regulator of T cell activationLorenz Vogt, Nicole Schmitz, Michael O Kurrer, et al.
NPJ Vaccines|November 18, 2024
Probing novel epitopes on the Plasmodium falciparum circumsporozoite protein for vaccine developmentPascal S Krenger, Magali Roques, Anne-Cathrine S Vogt, et al.
Poultry Science|March 29, 2023
Transcriptome analysis reveals critical factors for survival after adenovirus serotype 4 infectionYuhang Zhou, Qi Zheng, Shipeng Wang, et al.
Vaccines|July 26, 2019
Zika Virus-Derived E-DIII Protein Displayed on Immunologically Optimized VLPs Induces Neutralizing Antibodies without Causing Enhancement of Dengue Virus InfectionGustavo Cabral-Miranda, Stephanie M Lim, Mona O Mohsen, et al.
Vaccines|February 26, 2020
Correction: Zika Virus-Derived E-DIII Protein Displayed on Immunologically Optimized VLPs Induces Neutralizing Antibodies without Causing Enhancement of Dengue Virus Infection. Vaccines 2019, 7, 72Gustavo Cabral-Miranda, Stephanie M Lim, Mona O Mohsen, et al.
The Journal of Allergy and Clinical Immunology|April 9, 2018
Treating insect-bite hypersensitivity in horses with active vaccination against IL-5Antonia Fettelschoss-Gabriel, Victoria Fettelschoss, Franziska Thoms, et al.
Journal for Immunotherapy of Cancer|January 12, 2022
Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinomaMona O Mohsen, Daniel E Speiser, Justine Michaux, et al.
NPJ Vaccines|December 22, 2017
Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer's and cat allergyAndris Zeltins, Jonathan West, Franziska Zabel, et al.
Vaccines|April 30, 2021
Development of a Vaccine against SARS-CoV-2 Based on the Receptor-Binding Domain Displayed on Virus-Like ParticlesLisha Zha, Xinyue Chang, Hongxin Zhao, et al.
Vaccines|September 28, 2017
Microcrystalline Tyrosine (MCT®): A Depot Adjuvant in Licensed Allergy Immunotherapy Offers New Opportunities in MalariaGustavo Cabral-Miranda, Matthew D Heath, Ariane C Gomes, et al.
Pageof 51